

Eduard F Stange

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5494353/publications.pdf>

Version: 2024-02-01

55
papers

2,570
citations

394421

19
h-index

206112

48
g-index

170
all docs

170
docs citations

170
times ranked

3446
citing authors

#	ARTICLE	IF	CITATIONS
1	NF- κ B- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells by <i>Escherichia coli</i> Nissle 1917: a Novel Effect of a Probiotic Bacterium. <i>Infection and Immunity</i> , 2004, 72, 5750-5758.	2.2	437
2	Intestinal barrier in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 1165.	3.3	309
3	Inducible and Constitutive β -Defensins Are Differentially Expressed in Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2003, 9, 215-223.	1.9	260
4	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8772-8777.	7.1	183
5	Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 627-634.	1.6	151
6	Reduced mucosal antimicrobial activity in Crohn's disease of the colon. <i>Gut</i> , 2007, 56, 1240-1247.	12.1	138
7	Paneth's disease. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 523-531.	1.3	115
8	Inflammatory Bowel Disease: Crohn's disease and ulcerative colitis. <i>Deutsches Arzteblatt International</i> , 2016, 113, 72-82.	0.9	111
9	Microbiota and mucosal defense in IBD: an update. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 963-976.	3.0	98
10	Human colonic mucus is a reservoir for antimicrobial peptides. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e652-e664.	1.3	92
11	Synergistic Effects of Antimicrobial Peptides and Antibiotics against <i>Clostridium difficile</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5719-5725.	3.2	80
12	Crohn's disease-derived monocytes fail to induce Paneth cell defensins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14000-14005.	7.1	71
13	An Update Review on the Paneth Cell as Key to Ileal Crohn's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 646.	4.8	63
14	Human β -Defensin 2 Mediated Immune Modulation as Treatment for Experimental Colitis. <i>Frontiers in Immunology</i> , 2020, 11, 93.	4.8	52
15	TCF-1-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for Crohn's disease. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G487-G498.	3.4	41
16	Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. <i>F1000Research</i> , 2018, 7, 1207.	1.6	38
17	Gastric Antimicrobial Peptides Fail to Eradicate <i>Helicobacter pylori</i> Infection Due to Selective Induction and Resistance. <i>PLoS ONE</i> , 2013, 8, e73867.	2.5	33
18	Management of Crohn's disease – are guidelines transferred to clinical practice?. <i>United European Gastroenterology Journal</i> , 2015, 3, 371-380.	3.8	20

#	ARTICLE	IF	CITATIONS
19	In the Wnt of Paneth Cells: Immune-Epithelial Crosstalk in Small Intestinal Crohn's Disease. <i>Frontiers in Immunology</i> , 2017, 8, 1204.	4.8	20
20	Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 116-124.	1.9	20
21	Proteolytic Degradation of reduced Human Beta Defensin 1 generates a Novel Antibiotic Octapeptide. <i>Scientific Reports</i> , 2019, 9, 3640.	3.3	20
22	Antimicrobial Activity of High-Mobility-Group Box 2: a New Function to a Well-Known Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4782-4793.	3.2	19
23	Twenty-five years of biologicals in IBD: What's all the hype about?. <i>Journal of Internal Medicine</i> , 2021, 290, 806-825.	6.0	15
24	Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals. <i>United European Gastroenterology Journal</i> , 2014, 2, 216-225.	3.8	14
25	Gastrointestinal involvement in granulomatosis with polyangiitis and microscopic polyangiitis: histological features and outcome. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 412-419.	1.9	14
26	Recent advances in understanding and managing Crohn's disease. <i>F1000Research</i> , 2016, 5, 2896.	1.6	14
27	Î²-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor. <i>Frontiers in Immunology</i> , 2018, 9, 1735.	4.8	12
28	Association of FXR gene variants with cholelithiasis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 68-79.	1.5	11
29	Improvement of a 'Leaky' Intestinal Barrier. <i>Digestive Diseases</i> , 2017, 35, 21-24.	1.9	11
30	Fragmentation of Human Neutrophil Î±-Defensin 4 to Combat Multidrug Resistant Bacteria. <i>Frontiers in Microbiology</i> , 2020, 11, 1147.	3.5	11
31	Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue. <i>Scientific Reports</i> , 2018, 8, 12886.	3.3	10
32	The Case Against Using 5-Aminosalicyclates in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 613-615.	1.9	8
33	Medical Therapy of Perianal Crohn's Disease. <i>Visceral Medicine</i> , 2015, 31, 265-272.	1.3	8
34	Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482095925.	3.2	7
35	Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohn's Disease. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 125-137.	1.9	6
36	Infodemiology of Crohn's disease and Ulcerative colitis using Google Trends " an approach to investigate patient needs. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 224-233.	0.5	6

#	ARTICLE	IF	CITATIONS
37	Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, 1214-1223.	0.5	4
38	Antagonism of Adherent Invasive <i>E. coli</i> LF82 With Human α -defensin 5 in the Follicle-associated Epithelium of Patients With Ileal Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1116-1127.	1.9	4
39	Mitochondria in Ulcerative Colitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 352-353.	4.5	2
40	Therapeutic peptides in inflammatory bowel disease. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 455-466.	3.1	1
41	The debated role for thiopurines in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 172-174.	1.3	1
42	Antimicrobial Peptides in the Gut. , 2016, , 67-88.		1
43	129 - Oral Delivery of Human Beta-Defensin 2 is Reversibly Increasing Microbiome Diversity and is Effective in the Treatment of Experimental Colitis. <i>Gastroenterology</i> , 2018, 154, S-34-S-35.	1.3	1
44	Gut microbiome, metabolic syndrome, and atherosclerosis. , 2018, , 1082-1085.		1
45	In the case of nonresponse, what is the second-level treatment for induction of remission in Crohn's disease?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S251-S252.	1.9	0
46	Step-Up or Top-Down, Combination with Immunosuppression or Not?. <i>Frontiers of Gastrointestinal Research</i> , 0, , 169-177.	0.1	0
47	Sa1728 Chronic Alcohol Abuse Induces Paneth Cell Antimicrobial Expression in Gastric Mucosa - A Consequence of Wnt Signaling Aberrations?. <i>Gastroenterology</i> , 2015, 148, S-316.	1.3	0
48	Tu1835 Inflammatory Cells Enhance Defensin Expression via Peripheral Wnt Factors, Which Is Impaired in Ileal CD Patients. <i>Gastroenterology</i> , 2015, 148, S-915.	1.3	0
49	Human Endogenous Retroviruses and Residues of Ancient Times - are Differentially Expressed in Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S985.	1.3	0
50	HDAC Mediated Regulation of the Antimicrobial HBD2 Differs between Intestinal Cell Lines and Cultured Tissue. <i>Gastroenterology</i> , 2017, 152, S999.	1.3	0
51	Recombinant Production of Human Beta-Defensin 2 (HBD2) as an Immune-Modulator: Improvement of Experimental Colitis. <i>Gastroenterology</i> , 2017, 152, S567.	1.3	0
52	Influence of NOD2 Variants on <i>Trichuris suis ova</i> Treatment Outcome in Crohn's Disease. <i>Frontiers in Pharmacology</i> , 2018, 9, 764.	3.5	0
53	Tu1787 - Human Beta-Defensin 2 Suppresses TNF-Alpha Secretion in Human and Mouse Dendritic Cells Mediated by Chemokine Receptor 2. <i>Gastroenterology</i> , 2018, 154, S-1019.	1.3	0
54	A new kid on the budesonide block. <i>United European Gastroenterology Journal</i> , 2020, 8, 1141-1142.	3.8	0

#	ARTICLE	IF	CITATIONS
55	In Reply. Deutsches Ärzteblatt International, 2016, 113, 462.	0.9	0